Company to present updated data from the Phase 3 ENLIGHTED trial of Padeliporfin VTP in LG UTUC with topline data expected in ...

– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American ...

Vertical Data Inc. to highlight its vision for scalable AI infrastructure and capital solutions at a premier Wall ...

Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...

Twelve-month data from the VOLT-AF Global IDE study found that the Volt PFA System had an industry-leading success rate (84.2%) of freedom from documented rhythm recurrence among all competitive PFA ...

Initial Safety and Efficacy Data for NKTR-255, a Novel IL-15 Agonist, in Combination with Cetuximab in Solid Tumors Presented in Late-Breaking Abstract Session SAN FRANCISCO, Nov. 12, 2021 /PRNewswire ...

Please note: This item is from our archives and was published in 2022. It is provided for historical reference. The content may be out of date and links may no longer function. Tom King, CPA, has ...

MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Most white collar jobs involve creating presentations. And this can be a time-consuming, laborious process. Presentations include data points, and ensuring that these data points remain accurate and ...